At RayzeBio, every day is an opportunity to ignite meaningful change. As a wholly-owned subsidiary of Bristol Myers Squibb , RayzeBio blends the nimble, pioneering spirit of an emergent biotech with the global expertise and resources of a leading innovator in oncology. Our mission is to develop transformative radiopharmaceutical therapies that offer new hope for patients living with cancer. Here, you’ll join a multidisciplinary team where your ideas are valued, your expertise is amplified, and collaboration is at the heart of everything we do. From day one, expect to make an immediate impact—on our science, on our teams, and most importantly, on patients. Learn more about RayzeBio: https://careers.bms.com/rayzebio/
RayzeBio is a dynamic biotechnology company headquartered in San Diego, CA. Launched in late 2020 and recently acquired by Bristol Myers Squibb (BMS) as a wholly owned subsidiary, the company is focused on improving survival of people with cancer by harnessing the power of targeted radioisotopes. RayzeBio will operate as a standalone entity within the BMS organization, maintaining its biotech culture with the opportunity to leverage the best-in-class oncology capabilities of BMS. RayzeBio is developing innovative drugs against targets of solid tumors. The lead asset, RYZ101, is in Phase 3 testing for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
We are seeking a Radiopharmaceutical Medical Science Liaison (RPT-MSL) for RayzeBio to be trusted agile partner to the Thought Leader community. The role will engage in authentic, peer-to-peer scientific dialogue with leading RPT Thought Leaders and HCPs to strengthen RayzeBio’s scientific leadership, accelerate patient impact and shape the future of care. Your insights will inform clinical strategy, evidence generation and launch, ensuring that our innovative medicines reach patients in need. Led by a successful and experienced team, RayzeBio aims to be the global leader in radiopharmaceuticals.
Key Responsibilities
Build Scientific Partnerships: Facilitates scientific interactions and partnerships with Thought Leaders and HCPs including the multidisciplinary nuclear medicine team at top RPT institutions
Liaise with institutions to understand clinical and RPT-unique levers and barriers to patient access in the context of clinical trials
Lead high-impact scientific discussions and presentations that challenge conventional thinking and advance the standard of care. Educate on real-world evidence and clinical trial read-outs to key opinion leaders.
Support clinical development: identify and recommend sites for trials, engage with investigators and site staff to educate on the trial and asset and identify barriers to enrollment. Deliver solutions that address the barriers and support enrollment.
Gather Early, Actionable Insights: Conduct insight‐gathering sessions to uncover emerging clinical or diagnost